Oxaliplatin-Teva

Oxaliplatin

In combination w/ 5-fluorouracil & folinic acid for the treatment of metastatic (advanced) CRC or as additional treatment following surgical removal of tumour in the colon.

IV Adult, including elderly Infuse 85 mg/m² once every 2 wk over a 2-6 hr period.

Hypersensitivity to oxaliplatin or lactose monohydrate. Patients w/ reduced number of blood cells; tingling & numbness in fingers &/or toes; severe kidney problems. Lactation.

Do not use Al-containing inj material. Do not administer undiluted. Only dilute w/ 5% glucose soln. Do not combine w/ folinic acid in the same infusion bag. Always administer before fluoropyrimidines. Immediately stop administration in case of accidental leakage from vein & into surrounding tissues. Monitor abnormal feeling of pain or tingling in fingers, feet, & around the mouth or throat during or several hr after treatment. Regularly perform neurological exam. Check if blood cells are sufficient before starting treatment & before each subsequent course. Wash immediately & thoroughly w/ water if infusion soln comes into contact w/ skin or mucous membranes. Caution in patients w/ moderate kidney problems; any liver problems; history of allergic reaction to platinum-containing medicines (eg, carboplatin or cisplatin); inflammation of mucosa of the mouth; unexplainable breathing problems. May impair ability to drive or operate machinery. Do not use during pregnancy. Women should use contraceptive measures during & up until 4 mth after therapy. Men should not father a child during & up to 6 mth after treatment.

Bacterial or viral infection; anaemia, thrombocytopenia, neutropenia, leukopenia, lymphopenia; allergy/allergic reactions; peripheral neuropathy, abnormal sensation, change in taste, headache; nose bleeds; dyspnoea, coughing; diarrhoea, nausea, vomiting, abdominal pain, constipation, stomatitis/mucositis; skin disorder, hair loss; back pain; increased liver enzymes, blood alkaline phosphatase, blood bilirubin, & blood LDH; fever, fatigue, asthenia, pain, wt gain, inj site reactions, skin necrosis, low blood K, abnormal Na blood level, anorexia, changes in blood glucose level, changes in liver function. Rhinitis, resp tract infection, febrile neutropenia, neutropenic sepsis; rash, anaphylactic shock, bronchospasm, chest pain, angioedema, low BP; dizziness, neuritis motor, meningism, depression, sleeplessness; conjunctivitis, visual problems; haemorrhage, flushing, DVT, pulmonary embolism; hiccups; disturbed digestion, stomach pain, burping, dyspepsia, gastroesophageal reflux, rectal bleeding; hand & foot syndrome, erythematous rash, rash, hyperhidrosis, nail disorder; arthralgia, bone pain; haematuria, difficult or painful urination, abnormal frequency of urination; increased blood creatinine; wt loss, dehydration.

Incompatible w/ saline- or Cl-containing soln; alkaline medicinal products or soln; trometamol-containing prep.

Cytotoxic Chemotherapy

L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

P₁S₁S₃